Royalty Operating Income from 2010 to 2025

RPRX Stock

USD 33.76 0.01 0.03%

Royalty Pharma Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income will likely drop to about 1.2 B in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Royalty Pharma Plc generates from its operations. View All Fundamentals

Operating Income

First Reported

2002-09-30

Previous Quarter

735.1 M

Current Value

362 M

Quarterly Volatility

294.3 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.

Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Operating Income Growth Pattern

Below is the plot of the Operating Income of Royalty Pharma Plc over the last few years. Operating Income is the amount of profit realized from Royalty Pharma Plc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Royalty Pharma Plc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Royalty Pharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Royalty Operating Income Regression Statistics

	Arithmetic Mean	791,812,256
	Coefficient Of Variation	105.14
	Mean Deviation	718,991,099
	Median	977,499,000
	Standard Deviation	832,542,011
	Sample Variance	693126.2T
	Range	2.7B
	R-Value	0.74
	Mean Square Error	338379.2T
	R-Squared	0.54
	Significance	0
	Slope	129,018,735
	Total Sum of Squares	10396893T

Royalty Operating Income History

	2025	1.2 B
	2024	1.3 B
	2023	1.5 B
	2022	977.5 M
	2021	1.4 B
	2020	1.6 B
	2019	2.6 B

Other Fundumenentals of Royalty Pharma Plc

Non Operating Income Net Other

Royalty Pharma Operating Income component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Net Debt	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue	Capital Surpluse
Total Assets		0.96	0.84	0.19	0.96	-0.23	0.16	-0.37	-0.23	0.93	0.92	0.86	0.71	0.24	0.05	0.28	0.66	0.86	0.82	-0.85	-0.4	0.42	-0.42	0.67
Total Stockholder Equity	0.96		0.9	0.01	0.91	-0.23	0.12	-0.34	-0.25	0.86	0.88	0.74	0.78	0.25	-0.11	0.33	0.71	0.85	0.77	-0.81	-0.55	0.3	-0.6	0.68
Accounts Payable	0.84	0.9		-0.24	0.78	-0.2	0.03	-0.27	-0.36	0.78	0.86	0.48	0.84	0.12	0.12	0.2	0.75	0.87	0.73	-0.77	-0.73	0.16	-0.56	0.71
Short Term Investments	0.19	0.01	-0.24		0.11	0.32	0.03	-0.34	0.15	0.18	0.11	0.42	-0.21	0.03	-0.16	-0.05	-0.23	0.01	0.17	-0.14	0.6	0.51	0.44	-0.22
Total Liab	0.96	0.91	0.78	0.11		-0.33	0.37	-0.38	-0.12	0.95	0.92	0.89	0.71	0.29	0.05	0.33	0.68	0.77	0.68	-0.72	-0.46	0.4	-0.43	0.64
Treasury Stock	-0.23	-0.23	-0.2	0.32	-0.33		-0.42	-0.68	0.09	-0.31	-0.28	-0.26	-0.18	-0.03	0.06	-0.04	-0.15	-0.08	0.01	0.01	0.22	0.0	0.1	-0.07
Common Stock	0.16	0.12	0.03	0.03	0.37	-0.42		-0.16	0.54	0.37	0.28	0.34	-0.03	-0.24	-0.16	-0.25	-0.14	-0.24	-0.36	0.37	-0.14	-0.2	0.17	-0.31
Property Plant Equipment	-0.37	-0.34	-0.27	-0.34	-0.38	-0.68	-0.16		-0.27	-0.37	-0.36	-0.34	-0.25	-0.07	-0.03	-0.08	-0.23	-0.28	-0.26	0.26	0.16	-0.14	0.12	-0.22
Intangible Assets	-0.23	-0.25	-0.36	0.15	-0.12	0.09	0.54	-0.27		-0.13	-0.2	-0.01	-0.4	-0.32	-0.13	-0.34	-0.45	-0.5	-0.49	0.51	0.21	-0.32	0.31	-0.51
Net Tangible Assets	0.93	0.86	0.78	0.18	0.95	-0.31	0.37	-0.37	-0.13		0.98	0.83	0.73	0.15	0.12	0.23	0.66	0.79	0.72	-0.7	-0.45	0.39	-0.22	0.63
Retained Earnings	0.92	0.88	0.86	0.11	0.92	-0.28	0.28	-0.36	-0.2	0.98		0.74	0.82	0.16	0.08	0.25	0.73	0.85	0.75	-0.73	-0.54	0.39	-0.29	0.67
Total Current Assets	0.86	0.74	0.48	0.42	0.89	-0.26	0.34	-0.34	-0.01	0.83	0.74		0.37	0.22	0.05	0.23	0.37	0.57	0.63	-0.64	-0.02	0.45	-0.15	0.43
Net Debt	0.71	0.78	0.84	-0.21	0.71	-0.18	-0.03	-0.25	-0.4	0.73	0.82	0.37		0.43	-0.05	0.55	0.96	0.88	0.69	-0.7	-0.79	0.38	-0.63	0.85
Long Term Debt	0.24	0.25	0.12	0.03	0.29	-0.03	-0.24	-0.07	-0.32	0.15	0.16	0.22	0.43		-0.3	0.96	0.59	0.38	0.3	-0.37	-0.07	0.78	-0.59	0.54
Net Receivables	0.05	-0.11	0.12	-0.16	0.05	0.06	-0.16	-0.03	-0.13	0.12	0.08	0.05	-0.05	-0.3		-0.34	0.04	0.16	0.24	-0.21	-0.07	-0.12	0.32	0.23
Long Term Debt Total	0.28	0.33	0.2	-0.05	0.33	-0.04	-0.25	-0.08	-0.34	0.23	0.25	0.23	0.55	0.96	-0.34		0.69	0.47	0.39	-0.42	-0.18	0.7	-0.62	0.66
Net Invested Capital	0.66	0.71	0.75	-0.23	0.68	-0.15	-0.14	-0.23	-0.45	0.66	0.73	0.37	0.96	0.59	0.04	0.69		0.87	0.71	-0.72	-0.73	0.47	-0.67	0.94
Long Term Investments	0.86	0.85	0.87	0.01	0.77	-0.08	-0.24	-0.28	-0.5	0.79	0.85	0.57	0.88	0.38	0.16	0.47	0.87		0.94	-0.95	-0.54	0.5	-0.51	0.9
Short Long Term Debt	0.82	0.77	0.73	0.17	0.68	0.01	-0.36	-0.26	-0.49	0.72	0.75	0.63	0.69	0.3	0.24	0.39	0.71	0.94		-0.97	-0.27	0.5	-0.32	0.83
Capital Stock	-0.85	-0.81	-0.77	-0.14	-0.72	0.01	0.37	0.26	0.51	-0.7	-0.73	-0.64	-0.7	-0.37	-0.21	-0.42	-0.72	-0.95	-0.97		0.31	-0.53	0.46	-0.83
Net Working Capital	-0.4	-0.55	-0.73	0.6	-0.46	0.22	-0.14	0.16	0.21	-0.45	-0.54	-0.02	-0.79	-0.07	-0.07	-0.18	-0.73	-0.54	-0.27	0.31		0.18	0.63	-0.58
Short Term Debt	0.42	0.3	0.16	0.51	0.4	0.0	-0.2	-0.14	-0.32	0.39	0.39	0.45	0.38	0.78	-0.12	0.7	0.47	0.5	0.5	-0.53	0.18		-0.14	0.45
Current Deferred Revenue	-0.42	-0.6	-0.56	0.44	-0.43	0.1	0.17	0.12	0.31	-0.22	-0.29	-0.15	-0.63	-0.59	0.32	-0.62	-0.67	-0.51	-0.32	0.46	0.63	-0.14		-0.59
Capital Surpluse	0.67	0.68	0.71	-0.22	0.64	-0.07	-0.31	-0.22	-0.51	0.63	0.67	0.43	0.85	0.54	0.23	0.66	0.94	0.9	0.83	-0.83	-0.58	0.45	-0.59

Click cells to compare fundamentals

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	1.3 B	1.2 B
Non Operating Income Net Other	99.9 M	93.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Operating Income from 2010 to 2025

Latest Royalty Pharma's Operating Income Growth Pattern

Royalty Operating Income Regression Statistics

Royalty Operating Income History

Other Fundumenentals of Royalty Pharma Plc

Royalty Pharma Operating Income component correlations

About Royalty Pharma Financial Statements

Also Currently Popular

Additional Tools for Royalty Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY